Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures

Authors

  • Christopher F. Spurney MD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Heather Gordish-Dressman PhD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Alfredo D. Guerron MD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Arpana Sali MS,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Gouri S. Pandey PhD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Rashmi Rawat PhD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Jack H. Van Der Meulen PhD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Hee-Jae Cha PhD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Emidio E. Pistilli PhD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Terence A. Partridge PhD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Eric P. Hoffman PhD,

    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author
  • Kanneboyina Nagaraju DVM, PhD

    Corresponding author
    1. Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    • Research Center for Genetic Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA
    Search for more papers by this author

Abstract

The availability of animal models for Duchenne muscular dystrophy has led to extensive preclinical research on potential therapeutics. Few studies have focused on reliability and sensitivity of endpoints for mdx mouse drug trials. Therefore, we sought to compare a wide variety of reported and novel endpoint measures in exercised mdx and normal control mice at 10, 20, and 40 weeks of age. Statistical analysis as well as power calculations for expected effect sizes in mdx preclinical drug trials across different ages showed that body weight, normalized grip strength, horizontal activity, rest time, cardiac function measurements, blood pressure, total central/peripheral nuclei per fiber, and serum creatine kinase are the most effective measurements for detecting drug-induced changes. These data provide an experimental basis upon which standardization of preclinical drug testing can be developed. Muscle Nerve, 2008

Ancillary